^
Association details:
| Biomarker: | FGFR mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | nintedanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Published date:
07/20/2023
Excerpt:
ORR and disease control rate were 42.9% and 57.1%, respectively. The median PFS was 5.6 months and the median duration of response was 9.1 months. Median OS was 11.1 months….Single-agent nintedanib has demonstrated significant efficacy in FGFR-mutated, recurrent, or metastatic HNSCC patients...
DOI:
10.4143/crt.2023.433
